NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics


NovoCure Limited - Ordinary Shares (NVCR)

Today's Latest Price: $61.20 USD

1.66 (-2.64%)

Updated Jul 7 1:45pm

Add NVCR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVCR Stock Summary

  • NVCR's current price/earnings ratio is 711.64, which is higher than 99.34% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NVCR is currently 191.95, higher than 98.31% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 16.62, NovoCure Ltd has a higher such ratio than 91.58% of stocks in our set.
  • Stocks that are quantitatively similar to NVCR, based on their financial statements, market capitalization, and price volatility, are CEVA, ATRS, EGRX, INTT, and ANGI.
  • To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.
NVCR Daily Price Range
NVCR 52-Week Price Range

NVCR Stock Price Chart Technical Analysis Charts


NVCR Price/Volume Stats

Current price $61.20 52-week high $98.84
Prev. close $62.86 52-week low $53.40
Day low $60.99 Volume 312,405
Day high $62.73 Avg. volume 1,027,257
50-day MA $64.16 Dividend yield N/A
200-day MA $74.97 Market Cap 6.15B

NovoCure Limited - Ordinary Shares (NVCR) Company Bio


NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.


NVCR Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NVCR Latest Social Stream


Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NovoCure Ltd that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

Novocure enrolls last patient in Hepanova combo trial in advanced liver cancer

The last patient has been enrolled in Novocure's (NVCR) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months. The open-label trial includes 25 patients with advanced hepatocellular carcinoma that are...

Seeking Alpha | July 7, 2020

Novocure to Report Second Quarter 2020 Financial Results

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.

Business Wire | July 1, 2020

Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health?

NovoCure's (NASDAQ:NVCR) stock up by 5.6% over the past three months. As most would know, long-term fundamentals have...

Yahoo | June 18, 2020

Hedge Funds Have Never Been This Bullish On NovoCure Limited (NVCR)

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | June 8, 2020

Novocure launches MyLink tool in U.S.

Novocure (NVCR) has launched MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home.Novocure initiated a phased launch with an initial wave of 30 U.S. patients to be followed by a broad rollout to all patients in the coming months. Optune is...

Seeking Alpha | June 2, 2020

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo -10.20%
3-mo -11.94%
6-mo -24.45%
1-year -4.73%
3-year 239.06%
5-year N/A
YTD -27.38%
2019 151.70%
2018 65.74%
2017 157.32%
2016 -64.89%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8163 seconds.